Literature DB >> 16799362

The effects of managed care and competition on community-based clinical research.

William R Carpenter1, Bryan J Weiner, Arnold D Kaluzny, Marisa Elena Domino, Shoou-Yih Daniel Lee.   

Abstract

BACKGROUND: The National Institutes of Health is developing practice-based clinical research networks (PBRNs) to expedite the pace of scientific discovery and improve care quality. Anecdotal evidence suggests managed care penetration and provider competition negatively affect PBRN clinical research.
OBJECTIVE: The objective of this study is to examine the effects of environmental factors on clinical research performance in the National Cancer Institute's Community Clinical Oncology Program (CCOP). RESEARCH
DESIGN: This study examined 49 CCOPs in 34 states using longitudinal (1991-2001) generalized least-squares regression including fixed effects, using secondary data from the National Cancer Institute, Group Health Association of America, InterStudy, American Hospital Association, Area Resource Files, and the Current Population Survey. MEASURES: Performance was measured as CCOP-level accrual in treatment trials, cancer prevention and control (CP/C) trials, and all trials combined. HMO penetration served as a proxy for managed care penetration. Competition measures included both hospital competition and physician competition.
RESULTS: Managed care penetration was positively associated with accrual in areas of low to moderate penetration and negative in the areas of high penetration. Compared with areas with 5% penetration, areas with 15% penetration had 21% more treatment accrual and 66% more CP/C accrual. Compared with areas with 40% penetration, areas with 50% penetration had 11% lower treatment accrual and 3% lower CP/C accrual. CP/C accrual was more positively affected than treatment accrual. Greater hospital competition was associated with a decline in trial enrollment.
CONCLUSIONS: The healthcare environment appears to have a significant effect on accrual into community-based cancer treatment and CP/C clinical trials. Findings for treatment and CP/C accrual suggest each type of accrual is distinct and requires different strategies and administrative methods.

Entities:  

Mesh:

Year:  2006        PMID: 16799362     DOI: 10.1097/01.mlr.0000220269.65196.72

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  12 in total

1.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 2.  The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases.

Authors:  Hilal Maradit Kremers; Elena Myasoedova; Cynthia S Crowson; Guergana Savova; Sherine E Gabriel; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

3.  Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.

Authors:  Sara R Jacobs; Bryan J Weiner; Lori M Minasian; Marjorie J Good
Journal:  Contemp Clin Trials       Date:  2013-01-05       Impact factor: 2.226

4.  Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.

Authors:  William R Carpenter; Alice K Fortune-Greeley; Leah L Zullig; Shoou-Yih Lee; Bryan J Weiner
Journal:  Contemp Clin Trials       Date:  2011-10-02       Impact factor: 2.226

Review 5.  Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program.

Authors:  Lori M Minasian; William R Carpenter; Bryan J Weiner; Darrell E Anderson; Worta McCaskill-Stevens; Stefanie Nelson; Cynthia Whitman; Joseph Kelaghan; Ann M O'Mara; Arnold D Kaluzny
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

6.  Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.

Authors:  Bryan J Weiner; Sara R Jacobs; Lori M Minasian; Marjorie J Good
Journal:  J Oncol Pract       Date:  2012-05-01       Impact factor: 3.840

7.  Effect of state-mandated insurance coverage on accrual to community cancer clinical trials.

Authors:  Shellie D Ellis; William R Carpenter; Lori M Minasian; Bryan J Weiner
Journal:  Contemp Clin Trials       Date:  2012-06-08       Impact factor: 2.226

8.  Challenges and facilitators of community clinical oncology program participation: a qualitative study.

Authors:  Ann Scheck McAlearney; Kristin L Reiter; Bryan J Weiner; Lori Minasian; Paula H Song
Journal:  J Healthc Manag       Date:  2013 Jan-Feb

9.  Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.

Authors:  Ann Scheck McAlearney; Paula H Song; Kristin L Reiter
Journal:  Contemp Clin Trials       Date:  2012-08-19       Impact factor: 2.226

10.  Perceptions of Cancer Clinical Research Among African American Men in North Carolina.

Authors:  Laurel C Trantham; William R Carpenter; Lisa D DiMartino; Brandolyn White; Melissa Green; Randall Teal; Giselle Corbie-Smith; Paul A Godley
Journal:  J Natl Med Assoc       Date:  2015-12-02       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.